J
James N. Ingle
Researcher at Mayo Clinic
Publications - 403
Citations - 52917
James N. Ingle is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 82, co-authored 387 publications receiving 47883 citations. Previous affiliations of James N. Ingle include McMaster University & University of Rochester.
Papers
More filters
Journal Article
Evaluation of a fixed alternating treatment in patients with advanced breast cancer.
David L. Ahmann,Judith R. O'Fallon,Michael J. O'Connell,Harry F. Bisel,Richard G. Hahn,Frytak S,Edmonson Jh,Joseph Rubin,James N. Ingle,Larry K. Kvols +9 more
TL;DR: There were no differences noted in survival for the fixed alternating treatment group of patients, with respect to which induction regimen had been utilized to achieve initial response, and the three treatment programs including the fixed alternate treatment schedules had comparable median survivals of 21-24 months.
Journal ArticleDOI
Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.
Stephanie L. Safgren,Vera J. Suman,Matthew L. Kosel,Judith A. Gilbert,Sarah A. Buhrow,John L. Black,Donald W. Northfelt,Anil S. Modak,David Rosen,James N. Ingle,Matthew M. Ames,Joel M. Reid,Matthew P. Goetz +12 more
TL;DR: DM-BT was associated with CYP2D6 genotype and 3 and 6 months Endx Css but did not provide better discrimination of endoxifen steady-state concentrations compared with CYp2D7 genotype alone, and further studies are needed to identify additional factors which alter EndxCss.
Journal ArticleDOI
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27
Judith Anne W. Chapman,Lois E. Shepherd,James N. Ingle,Hyman B. Muss,Kathleen I. Pritchard,Karen A. Gelmon,Timothy J. Whelan,C. Elliott,Paul E. Goss +8 more
TL;DR: Baseline patient and tumor characteristics differentially affected type of death in the MA.27 trial with women 70 or older experiencing more non-breast cancer death, a phase III adjuvant breast cancer trial of exemestane versus anastrozole.
Journal ArticleDOI
Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes
Duan Liu,Ming Fen Ho,Daniel J. Schaid,Steven E. Scherer,Krishna R. Kalari,Mohan Liu,Joanna M. Biernacka,Vivien C. Yee,Jared M. Evans,Erin E. Carlson,Matthew P. Goetz,Michiaki Kubo,D. Lawrence Wickerham,Liewei Wang,James N. Ingle,Richard M. Weinshilboum +15 more
TL;DR: Additional functional SNPs in ZNF423 that were associated with SNP and SERM-dependent alternations in ER binding and transcriptional regulation for an ERE at a distance from the SNPs are identified, providing novel insight into mechanisms of SERM effect.
Journal ArticleDOI
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
Swaathi Jayaraman,Xiaonan Hou,Mary J. Kuffel,Vera J. Suman,Tanya L. Hoskin,Kathryn E. Reinicke,David G. Monroe,Krishna R. Kalari,Xiaojia Tang,Megan A. Zeldenrust,Jingfei Cheng,Elizabeth S. Bruinsma,Sarah A. Buhrow,Renee M. McGovern,Stephanie L. Safgren,Chad A. Walden,Jodi M. Carter,Joel M. Reid,James N. Ingle,Matthew M. Ames,John R. Hawse,Matthew P. Goetz +21 more
TL;DR: In endocrine-sensitive and letrozole-resistant breast tumors, Z-endoxifen results in robust antitumor and antiestrogenic activity compared to tamoxifens and aromatase inhibitor monotherapy.